Back to Search
Start Over
Viral Dynamics and Their Relations to Baseline Factors and Longer Term Virologic Responses in Treatment-Naive HIV-1–Infected Patients Receiving Abacavir in Combination with HIV-1 Protease Inhibitors
- Source :
- JAIDS Journal of Acquired Immune Deficiency Syndromes. 33:557-563
- Publication Year :
- 2003
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2003.
-
Abstract
- From a study of 71 HIV-1-infected patients receiving abacavir in combination with 1 of 5 different HIV-1 protease inhibitors (indinavir, ritonavir, saquinavir, nelfinavir, or amprenavir), we found that the baseline HIV-1 RNA levels were highly predictive of the viral decay rates. The baseline HIV-1 RNA levels were negatively correlated with the first phase viral decay rates (r = -0.77, P < 0.001) and positively correlated with the second phase viral decay rates (r = 0.68, P < 0.001). In addition, the first phase viral decay rate was positively correlated with CD4+ cell increases. No significant correlation was found between viral decay rates and longer term (24 weeks) virologic responses, and no difference in viral decay rates was found among the 5 study regimens. These data suggest that the potency of the 5 treatment regimens was similar and was not predictive of long-term virologic failure.
- Subjects :
- Adult
Male
Time Factors
Adolescent
viruses
HIV Infections
Biology
Amprenavir
Abacavir
Indinavir
medicine
Humans
Pharmacology (medical)
Protease inhibitor (pharmacology)
virus diseases
HIV Protease Inhibitors
Middle Aged
Viral Load
Virology
Dideoxynucleosides
CD4 Lymphocyte Count
Infectious Diseases
Nelfinavir
Immunology
HIV-1
RNA, Viral
Reverse Transcriptase Inhibitors
Drug Therapy, Combination
Female
Ritonavir
Viral load
Saquinavir
medicine.drug
Subjects
Details
- ISSN :
- 15254135
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Accession number :
- edsair.doi.dedup.....0e19e01c97b3f7ef69309d5b4d06569a
- Full Text :
- https://doi.org/10.1097/00126334-200308150-00002